MAFP (methyl-arachidonoyl-fluoro-phosphonate) is an irreversible inhibitor of cPLA2. Research has shown that this compound is also one of the most potent of the FAAH (anandamide amidohydrolase; Fatty acid amide hydrolase) inhibitors. Further studies suggest that MAFP completely blocks FAAH enzyme activity, the enzyme responsible for hydrolysis of endogenous cannabinoid ligand anandamide. Mechanistic studies suggest that this reagent specifically targets and phosphorylates arachidonyl binding sites. MAFP is an inhibitor of AChE. MAFP is an inhibitor of CB1. MAFP is an inhibitor of group VI iPLA2.
1. De Petrocellis, L., et al. 1997. Biochem. Biophys. Res. Commun. 231: 82-88. PMID: 9070224
2. Deutsch, D.G., et al. 1997. Biochem. Pharmacol. 53: 255-260. PMID: 9065728
3. Martin, B.R., et al. 2000. J. Pharmacol. Exp. Ther. 294: 1209-1218. PMID: 10945879
See how others have used MAFP (CAS 188404-10-6). Click on the entry to view the PubMed entry .
PMID: # 23451150 2013. PLoS ONE. 8: e57081.
PMID: # 23774297 2013. Biochimie. 95: 1677-88.
PMID: # 22767227 Cai, Q. et al. 2012. FASEB J. 26: 3306-20.
PMID: # 28455813 In Vitro Cell Dev Biol Anim. 421-429.